Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
Psoriasis is a chronic inflammatory skin disease affecting nearly 10% of dermatologic patients in Malaysia. Treatment options include topical agents and phototherapy as well as nonbiologic and biologic systemic therapy. Mild psoriasis can often be managed with topical agents. However, managing moder...
Main Authors: | Chan, L.C (Author), Ch'Ng, C.C (Author), Heng, A. (Author), Johar, A. (Author), Mohd Safdar, N.A (Author), Muniandy, P. (Author), Taib, T. (Author), Tan, W.C (Author), Tey, K.E (Author), Thevarajah, S. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019
|
Subjects: | |
Online Access: | View Fulltext in Publisher View in Scopus |
Similar Items
-
Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy
by: Georgios Kokolakis, et al.
Published: (2020-07-01) -
Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
by: Kivelevitch D, et al.
Published: (2019-04-01) -
Comparative study of clinical and dermoscopic features in nail psoriasis
by: Naphisabet Wanniang, et al.
Published: (2020-01-01) -
Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
by: Rossana Tiberio, et al.
Published: (2019-09-01) -
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01)